These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15737074)

  • 1. Iterative partial least squares with right-censored data analysis: a comparison to other dimension reduction techniques.
    Huang J; Harrington D
    Biometrics; 2005 Mar; 61(1):17-24. PubMed ID: 15737074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual analysis in linear regression models with an interval-censored covariate.
    Topp R; Gómez G
    Stat Med; 2004 Nov; 23(21):3377-91. PubMed ID: 15490424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inference for a linear regression model with an interval-censored covariate.
    Gómez G; Espinal A; W Lagakos S
    Stat Med; 2003 Feb; 22(3):409-25. PubMed ID: 12529872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
    Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virologic response to ritonavir-boosted protease inhibitors.
    Marcelin AG; Flandre P; Peytavin G; Calvez V
    AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimension reduction in the linear model for right-censored data: predicting the change of HIV-I RNA levels using clinical and protease gene mutation data.
    Huang J; Harrington D
    Lifetime Data Anal; 2004 Dec; 10(4):425-43. PubMed ID: 15690994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    Delaugerre C; Peytavin G; Dominguez S; Marcelin AG; Duvivier C; Gourlain K; Amellal B; Legrand M; Raffi F; Costagliola D; Katlama C; Calvez V
    J Med Virol; 2005 Nov; 77(3):345-50. PubMed ID: 16173015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization.
    Rabinowitz M; Myers L; Banjevic M; Chan A; Sweetkind-Singer J; Haberer J; McCann K; Wolkowicz R
    Bioinformatics; 2006 Mar; 22(5):541-9. PubMed ID: 16368772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of multiple imputation to the analysis of censored regression data.
    Wei GC; Tanner MA
    Biometrics; 1991 Dec; 47(4):1297-309. PubMed ID: 1786320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
    Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
    J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables.
    Hammel JP; Bhavnani SM; Jones RN; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2006 Jan; 50(1):62-7. PubMed ID: 16377668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
    Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
    J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
    Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M;
    J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covariate analysis of competing-risks data with log-linear models.
    Larson MG
    Biometrics; 1984 Jun; 40(2):459-69. PubMed ID: 6487729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-over trials with censored data.
    Feingold M; Gillespie BW
    Stat Med; 1996 May; 15(10):953-67. PubMed ID: 8783435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.